Optimization of Retroviral Gene Transfer Protocol to Maintain the Lymphoid Potential of Progenitor Cells
- 10 February 2001
- journal article
- research article
- Published by Mary Ann Liebert Inc in Human Gene Therapy
- Vol. 12 (3) , 291-301
- https://doi.org/10.1089/10430340150218422
Abstract
We have attempted to improve retrovirus-mediated gene transfer efficacy into hematopoietic progenitor cells (HPCs) without causing them to lose their lymphoid potential. Highly purified CD34+ cells on CH-296 fibronectin fragments have been transduced with three different cytokine combinations. Murine CD2 was used as a marker gene. Transgene expression was assayed by FACS analysis shortly after transduction of CD34+ cells and after long-term culture (LTC) extended by differentiation of various lymphoid lineages: NK cells, B cells, and dendritic cells. Compared with the historical cytokine mix, i.e., SCF (stem cell factor) + IL-3 (interleukin 3) + IL-6, the combination SCF + FL (Flt-3 ligand) + M-GDF (megakaryocyte growth and differentiation factor) + IL-3 significantly improved the total number of viable cells and CD34+ cells after transduction and the long term-cultured progenitors after 6 weeks. In addition, the combination of SCF + FL + M-GDF + IL-3 maintained more efficiently the lymphoid potential of the progeny of transduced long term-cultured CD34+ cells, as attested by the significantly higher number of CD56+, CD19+, and CD1a+ cells recovered when FL and M-GDF were added to SCF + IL-3. Thus, even though additional improvements may still be needed in transduction of HPCs, these conditions were adopted for a clinical trial of gene therapy for X-linked severe combined immunodeficiency.Keywords
This publication has 74 references indexed in Scilit:
- Gene Therapy of Human Severe Combined Immunodeficiency (SCID)-X1 DiseaseScience, 2000
- Ex VivoCulture of Cord Blood CD34+Cells Expands Progenitor Cell Numbers, Preserves Engraftment Capacity in Nonobese Diabetic/Severe Combined Immunodeficient Mice, and Enhances Retroviral Transduction EfficiencyHuman Gene Therapy, 1999
- Optimization of Retroviral Gene Transduction of Mobilized Primitive Hematopoietic Progenitors by Using Thrombopoietin, Flt3, and Kit Ligands and RetroNectin CultureHuman Gene Therapy, 1999
- Retroviral Transfer of the Glucocerebrosidase Gene into CD34+ Cells from Patients with Gaucher Disease: In Vivo Detection of Transduced Cells without MyeloablationHuman Gene Therapy, 1998
- Differential cytokine effects on primitive (CD34+CD38-) human hematopoietic cells: novel responses to Flt3-ligand and thrombopoietin.The Journal of Experimental Medicine, 1996
- Stem Cell Factor as a Survival and Growth Factor in Human Normal and Malignant HematopoiesisActa Haematologica, 1996
- Bone marrow extracellular matrix molecules improve gene transfer into human hematopoietic cells via retroviral vectors.Journal of Clinical Investigation, 1994
- Human cord blood cells as targets for gene transfer: potential use in genetic therapies of severe combined immunodeficiency disease.The Journal of Experimental Medicine, 1993
- Interleukin-3 and Hematopoiesis (Part 1 of 2)Published by S. Karger AG ,1992
- Heparan sulphate bound growth factors: a mechanism for stromal cell mediated haemopoiesisNature, 1988